Skip to main content
Clinical Trials/NCT00545961
NCT00545961
Unknown
Phase 4

Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study

Oulu University Hospital3 sites in 1 country120 target enrollmentNovember 2007

Overview

Phase
Phase 4
Intervention
placebo
Conditions
Acute Respiratory Infection
Sponsor
Oulu University Hospital
Enrollment
120
Locations
3
Primary Endpoint
Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.
Last Updated
18 years ago

Overview

Brief Summary

The purpose of this study is to find out whether the children with respiratory infection and the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus benefit from antimicrobial treatment.

Detailed Description

Acute sinusitis is one of the most common disease in children requiring antimicrobial treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial culture results obtained from the nasal middle meatus are comparable to those obtained from sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection predicts longer duration of signs and symptoms of common cold. In this randomized placebo-controlled study, the effect of the antimicrobial treatment (amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection. The duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the results are compared between the treatment groups.

Registry
clinicaltrials.gov
Start Date
November 2007
End Date
December 2009
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • acute respiratory infection with nasal symptoms (nasal obstruction or discharge)
  • seeking medical help from health centre for the respiratory symptoms
  • pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from right or left nasal middle meatus in the endoscopically taken swab culture sampling taken by a study investigator (all microbiological analyses are done by the National Public Health Institute´s microbiological laboratory in Oulu)

Exclusion Criteria

  • otitis, tonsillitis or other disease requiring antimicrobial treatment
  • respiratory infection within 4 weeks of screening
  • antimicrobial treatment within 4 weeks of screening
  • allergy to penicillin or amoxicillin

Arms & Interventions

1

placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug

Intervention: placebo

2

amoxicillin-clavulanate acid

Intervention: amoxicillin clavulanate acid

Outcomes

Primary Outcomes

Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.

Time Frame: within the first 3 weeks after enrolment

Secondary Outcomes

  • duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)(within the first three weeks after enrolment)
  • number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines)(within the first three weeks after the enrolment)
  • number of days the child is not at school and that the parents are not at work(within the first three weeks after enrolment)

Study Sites (3)

Loading locations...

Similar Trials